Skip to main content

Table 2 Comparison of underlying diseases in COVID-19 patients with GI or respiratory symptoms

From: Gastrointestinal implications in COVID-19

Variable

Total

GIA (n = 92)

RA (n = 184)

GIR (n = 151)

WGIR (n = 80)

P-value*

N (%)

N (%)

N (%)

N (%)

N (%)

Chronic cardiovascular disease

60 (11.8)

16 (17.4)

23 (12.5)

11 (7.3)

10 (12.5)

0.120

Hypertension

128 (25.3)

28 (30.4)

43 (23.5)

35 (23.2)

22 (27.5)

0.539

Hyperthyroidism

1 (0.2)

0 (0)

1 (0.5)

0 (0)

0 (0)

1.000†

Hypothyroidism

13 (2.6)

2 (2.2)

5 (2.7)

5 (3.3)

1 (1.3)

0.868†

G6PD deficiency

5 (1.0)

0 (0)

2 (1.1)

0 (0)

3 (3.8)

0.025†

Hyperlipidemia

30 (5.9)

6 (6.5)

13 (7.1)

9 (6.0)

2 (2.5)

0.537

Malignant neoplasm

8 (1.6)

5 (5.4)

0 (0)

3 (2.0)

0 (0)

0.003†

Chronic hematologic disease

9 (1.8)

2 (2.2)

3 (1.6)

2 (1.3)

2 (2.5)

0.845†

Chronic neurologic disorder

17 (3.4)

4 (4.3)

5 (2.7)

5 (3.3)

3 (3.8)

0.869†

Obesity

0 (0)

3 (1.6)

0 (0)

0 (0)

0 (0)

0.268†

Chronic pulmonary disease

12 (2.4)

4 (4.3)

4 (2.2)

3 (2.0)

1 (1.3)

0.608†

Diabetes

116 (22.9)

24 (26.1)

46 (25.0)

24 (15.9)

22 (27.5)

0.090

Asthma

27 (5.3)

3 (3.3)

15 (8.2)

6 (4.0)

3 (3.8)

0.264†

Chronic kidney disease

29 (5.7)

9 (9.8)

7 (3.8)

6 (4.0)

7 (8.8)

0.099

Rheumatologic disorder

7 (1.4)

1 (1.1)

0 (0)

2 (1.3)

4 (5.0)

0.015†

Liver disease

10 (2.0)

6 (6.5)

1 (0.5)

1 (0.7)

2 (2.5)

0.005†

  1. RA respiratory alone, GIA gastrointestinal alone, GIR gastrointestinal and respiratory, WGIR without gastrointestinal or respiratory, N number, G6PD glucose-6-phosphate dehydrogenase
  2. *Analyzed by Chi-squared test
  3. †Analyzed by Fisher’s exact test